Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.44 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17120707 | 0.86 | MAPT (0.54) | ESR2CNR2GRM2ALDH1A1LMNA | |
| SCHEMBL17120706 | 0.86 | KDM4E (0.48) | ESR2CNR2ALDH1A1LMNAKDM4E | |
| SCHEMBL17120708 | 0.84 | KDM4E (0.56) | ESR2CNR2CCNA2CDK2ALDH1A1 | |
| SCHEMBL24989031 | 0.84 | HSD17B10 (0.56) | ESR2PRKAB1ALDH1A1LMNAKDM4E | |
| SCHEMBL17120693 | 0.79 | CNR2 (0.46) | CNR2GRM2 | |
| Cyclohexane SCHEMBL10610234 | 0.79 | ESR2 (0.62) | ESR2CNR2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL31410710 | 0.76 | ESR2 (0.76) | ESR2ARPTPN5ALDH1A1KDM4E | |
| SCHEMBL17120705 | 0.75 | KDM4E (0.67) | CNR2ALDH1A1LMNATDP1KDM4E | |
| SCHEMBL3892797 | 0.75 | ALDH1A1 (0.49) | ARALDH1A1TDP1KDM4EMEN1 | |
| SCHEMBL28698328 | 0.75 | CNR2 (0.55) | CNR2ALDH1A1LMNATDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208916-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2024-06-27 | — | — | US | disclosed |
| US-20240208916-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2024-06-27 | — | — | US | disclosed |
| US-11718596-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718596-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| EP-3119761-B1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | AMYDIS DIAGNOSTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210369873-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF TRAUMATIC BRAIN INJURY | Amydis, Inc. | 2021-12-02 | — | — | US | disclosed |
| US-20210371390-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2021-12-02 | — | — | US | disclosed |
| WO-2021055639-A1 | METHODS OF DETECTING NEUROLOGICAL DISORDERS VIA BINDING TO PHOSPHORYLATED TAU PROTEIN | SARRAF STELLA (US) | 2021-03-25 | — | — | WO | disclosed |
| US-10934264-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200123118-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-04-23 | — | — | US | disclosed |
| US-10370345-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-06 | — | — | US | disclosed |
| US-10005745-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005745-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170248616-A1 | IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT | Amydis, Inc. | 2017-08-31 | — | — | US | disclosed |
| US-20170248616-A1 | IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT | Amydis, Inc. | 2017-08-31 | — | — | US | disclosed |
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2016-11-10 | — | — | US | disclosed |
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2016-11-10 | — | — | US | disclosed |
| WO-2015143185-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | AMYDIS DIAGNOSTICS (US) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718596-B2 | Amyloid targeting agents and methods of using the same | APP, CRYAA, APBA1 | ESR2 4446/4885AR 4752/4885CNR2 4195/4885 |
| US-20200123118-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, CRYAA, APBA1 | ESR2 4446/4885AR 4752/4885CNR2 4195/4885 |
| US-20210369873-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF TRAUMATIC BRAIN INJURY | S100B, FABP7, CRYAB | ESR2 4647/4885AR 4781/4885CNR2 2853/4885 |
| US-20210371390-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, CRYAA, APBA1 | ESR2 4446/4885AR 4752/4885CNR2 4195/4885 |
| US-20240208916-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, CRYAA, APBA1 | ESR2 4446/4885AR 4752/4885CNR2 4195/4885 |
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, APBA1, CRYAA | ESR2 4400/4885AR 4753/4885CNR2 4290/4885 |
| US-10370345-B2 | Amyloid targeting agents and methods of using the same | APP, CRYAA, APBA1 | ESR2 4446/4885AR 4752/4885CNR2 4195/4885 |
| US-10934264-B2 | Amyloid targeting agents and methods of using the same | APP, CRYAA, APBA1 | ESR2 4446/4885AR 4752/4885CNR2 4195/4885 |
| US-10005745-B2 | Amyloid targeting agents and methods of using the same | APP, APBA1, CRYAA | ESR2 4400/4885AR 4753/4885CNR2 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.